TTARlatamab for Medullary thyroid Carcinoma, a European multicenter, non-randomized phase II trial with an external control arm (TARMAC - CETAG)
Key facts
- Who runs it
- Institut Gustave Roussy
- Where
- France8 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 37 people, planned
- Starts
- 7 Dec 2026
- Expected to end
- 7 Dec 2029
- Type of study
- Interventional
- Record updated
- 19 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (42)Hide the full registry criteria
Who can take part
- Patient with a medullary thyroid carcinoma
- Patients must have a minimum life expectancy of 3 months
- Patients must have adequate bone marrow reserve and organ function, based on local laboratory data within 28 days prior to cycle 1, day 1 defined in Table 2
- Patients must have baseline oxygen saturation > 90% on room air
- Females of reproductive/childbearing potential must have a negative serum pregnancy test at screening and must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 60 days for females after the last dose of study drug
- Female patients must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 60 days after the final study drug administration
- Male patients must be surgically sterile or must withhold heterosexual intercourse or must be willing to use a highly effective birth control upon enrollment, during the treatment period, and for at least 60 days following the last dose of study drug
- Male patients must not freeze or donate sperm starting at screening and throughout the study period, and at least 60 days after the final study drug administration
- Patients must understand, sign and date the written informed consent from prior to any protocol-specific procedures performed. Patients should be able and willing to comply with study visits and procedures as per protocol
- Patients must be affiliated to a Social Security System or beneficiary of the same
- Patient with an advanced or metastatic disease
- Patient who has a documented progressive disease according to RECIST in the prior 14 months (local review) or a symptomatic tumor burden and calcitonin doubling time < 1 year
- After at least one line of selective RET inhibitor (selpercatinib or praseltinib) in RET-mutant patients
- Whatever the line in RET wild-type patients
- Patients must have at least one radiologically measurable lesion according to response evaluation criteria in solid tumors (RECIST) v1.1 criteria
- Patient must have an archival tumor block available
- Age ≥ 18 years
- ECOG performance status ≤ 1
Who cannot take part
- Any evidence of primary malignancy other than metastatic/locally advanced MTC within 3 years prior to cycle 1 day 1, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated
- Patients with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment
- Patients with history or evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patient is eligible if no acute symptoms of coronavirus disease 2019 (COVID-19) within 14 days prior to first dose of tarlatamab (counted from day of positive test for asymptomatic subjects)
- Patient with active or prior documented autoimmune or inflammatory disorders, including but not limited to inflammatory bowel disease [e.g. colitis or Crohn's disease], diverticulitis with the exception of diverticulosis, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangitis), rheumatoid arthritis, hypophysitis, uveitis within the past 3 years prior to the start of treatment. The following are exceptions to this criterion: a. Patient with auto-immune alopecia b. Patient with Grave's disease, vitiligo or psoriasis not requiring systemic treatment within the last 2 years c. Patient with hypothyroidism (e.g. following Hashimoto syndrome) stable on thyroid hormone replacement
- Prior history of severe or life-threatening events from any immune-mediated therapy
- Participation in another clinical trial (<30 days or < 5 half-lives, whichever is longer) evaluating an experimental drug (except non-interventional research)
- Patients who experienced recurrent pneumonitis (grade 2 or higher) or severe, life-threatening immune-mediated AEs or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents
- Prior treatment with tarlatamab or any selective inhibitor of the DLL3 pathway
- Evidence of spinal cord compression or brain metastases, defined as being clinically active and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Patients with clinically inactive or treated brain metastases who are asymptomatic (ie, without neurologic signs or symptoms and do not require treatment with corticosteroids or anticonvulsants) may be included in the study. Patients must have a stable neurologic status for at least 2 weeks prior to cycle 1 day 1
- Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to grade 1 or baseline according to the NCI-CTCAE v5.0
- Other thyroid cancer subtype (differentiated, poorly differentiated and anaplastic thyroid carcinoma)
- Any evidence of severe or uncontrolled systemic diseases including active bleeding diatheses, active infection, psychiatric illness/social situations, geographical factors, substance abuse, or other factors which in the Investigator’s opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required
- Patient with history of arterial thrombosis (eg, stroke or transient ischemic attack) within 12 months of first dose of tarlatamab
- Participant with active hepatitis B (including acute HBV or chronic HBV) or HCV (RNA detected by qualitative assay). HCV RNA testing is not required in participants with negative HCV antibody testing
- Patient with diagnosis of human immunodeficiency virus (HIV). Patients with HIV infection on antiviral therapy and undetectable viral load are allowded with a requirement for regular monitoring for reactivation for the duration of treatment on study per local or institutional guidelines
- Patients with evidence of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis) or is suspected to have such disease by imaging during screening
- Patients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- Patients with a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients of tarlatamab
- Inadequate washout period prior to cycle 1 day 1, defined as: a. Whole brain radiation therapy or stereotactic brain radiation therapy <14 days b. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation <28 days or palliative radiation therapy <7 days c. Any investigational agents or other anticancer drug(s) from a previous cancer treatment regimen or clinical study <30 days or < 5 half-lives, whichever is longer, prior to first dose of tarlatamab. Conventional chemotherapy eligible if at least 14 days or < 5 half-lives, whichever is longer, have elapsed and if all treatment-related toxicity has been resolved to grade ≤1 d. Major surgery (excluding placement of vascular access) < 21 days e. Live virus and live-attenuated vaccination <28 days f. Systemic steroid therapy or other immunosuppressive therapy < 7 days
- Patients with evidence of any leptomeningeal disease
- Uncontrolled or significant cardiovascular disease prior to cycle 1 day 1, including: a. QTcF interval > 500 ms according to Fridericia's formula (QTcF) and assessed based on triplicate ECGs, approximately 1 minute apart b. LVEF <50% by either echocardiogram or multigated acquisition (MUGA) scan c. Myocardial infarction within 6 months d. NYHA > class II within 6 months (appendix 9) e. Clinically significant pericardial effusion as determined by an ECHO or MUGA scan
- Patients with clinically significant pleural effusion will be excluded. Pleural effusion managed with indwelling pleural catheter (eg, PleurX) are allowed
- Female patients who are pregnant or breastfeeding or intend to become pregnant during the study
- Patients under guardianship or deprived of his/her liberty by a judicial or administrative decision or incapable of giving his/her consent
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Medullary thyroid carcinoma
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the investigator-based progression-free survival (PFS) rate at 6 months under tarlatamab monotherapy in patients with progressive metastatic medullary thyroid carcinoma whatever the line, but at least one selective RET inhibitor (pralsetinib or selpercatinib) in case of RET mutation
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- TARlatamab for Medullary thyroid Carcinoma, a European multicenter, non-randomized phase II trial with an external control arm (TARMAC-CETAG)
- Criteria questions
- Built from 2025-521574-33-00, who can take part
- Record updated
- 19 November 2026